Richard S. Geary - Feb 3, 2023 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Signature
By: Patrick R. O'Neil, attorney-in-fact For: Richard S. Geary
Stock symbol
IONS
Transactions as of
Feb 3, 2023
Transactions value $
-$78,070
Form type
4
Date filed
2/7/2023, 04:36 PM
Previous filing
Jan 19, 2023
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Award $0 +3.82K +5.42% $0.00 74.3K Feb 3, 2023 Direct F1
transaction IONS Common Stock Sale -$78.1K -1.92K -2.58% $40.66 72.4K Feb 6, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.62 to $40.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.